- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03568838
Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention (PENNYWISE)
Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention Compared With Standard of Care Therapy - The PENNYWISE Feasibility Study
Study Overview
Detailed Description
Delayed absorption of oral P2Y12 inhibitors in patients undergoing primary percutaneous coronary intervention (PPCI) may increase the risk of stent thrombosis. Parenteral treatment is needed mitigate this risk.
We have recently shown a novel regimen of enoxaparin (bolus 0.75 mg/kg followed by an infusion of 0.75 mg/kg/6h) to provide consistent antithrombotic effects until the end of the infusion (1). We have also demonstrated the high prevalence of delayed platelet inhibition in opiate-treated patients (1).
This is a feasibility study for a larger randomised controlled trial (RCT). We aim to assess recruitment rate and collect pilot data on safety and efficacy. This will be a single-centre, open-label RCT comparing this novel regimen of enoxaparin to the local standard-of-care which usually consists of unfractionated heparin and a glycoprotein IIb/IIIa inhibitor. The study population will be opiate-treated patients undergoing PPCI. Pre PPCI, patients will be allocated in 1:1 ratio using a simple randomisation method using sealed envelopes, to either enoxaparin 0.75 mg/kg bolus followed by 0.75 mg/kg infusion over 6 hours (n=50) or the standard-of-care of UFH and tirofiban (n=50).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S5 7AU
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18
- Confirmation of the diagnosis of STEMI by the clinical team on the basis of history and ECG changes
- Intention to proceed with PPCI
- Treated with opiates for analgesia
- Feasibility to obtain informed verbal consent pre PPCI
Exclusion Criteria:
- Active bleeding that cannot be controlled by local measures
- Pregnant patients
- Patients with end-stage renal failure requiring renal replacement therapy
- Patients with cardiogenetic shock
- Known thrombocytopenia (Platelet count <100,000)
- Known history of intracranial haemorrhage
- Known current treatment with oral anticoagulants
- Known history of major surgery or trauma or history of GI/GU haemorrhage within the last month
- Known intracranial malignancy or aneurysm
- Known allergy to enoxaparin
- known hypersensitivity to benzylalcohol
- Patients with known acute bacterial endocarditis
- Known active gastric or duodenal ulceration
- Inability to easily understand verbal information given in English for any reason
- Inability to give informed consent due to either temporary or permanent mental incapacity
- Current participation, or participation within the last month, in an interventional clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Enoxaparin
Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
|
Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
|
No Intervention: Standard Therapy
Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment Rate
Time Frame: Through study completion, average 1 year
|
Recruitment rate over the study period
|
Through study completion, average 1 year
|
Bleeding rates within 24 hours
Time Frame: Through study completion, average 1 year
|
These rates will be compared between the two treatment groups.
Trivial bleeding related to access site will be excluded.
Details on bleeding events will be collected and subsequently classified according to BARC types 2-5
|
Through study completion, average 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute stent thrombosis rate in each treatment arm
Time Frame: Through study completion, average 1 year
|
Acute stent thrombosis rate in each treatment arm (within 24 hours).
These rates will be compared between the two treatment groups.
|
Through study completion, average 1 year
|
Rates of ST-segment resolution in each treatment arm
Time Frame: Through study completion, average 1 year
|
Comparison will be undertaken between presentation ECG and ECG performed 1 hour post PPCI.
We will compare rates of ST segment resolution between the two treatment groups.
|
Through study completion, average 1 year
|
Rates of the composite outcomes
Time Frame: Through study completion, average 1 year
|
Rates of the composite outcome of recurrent myocardial infarction, ischaemic stroke or cardiovascular death within 30 days of STEMI.
These rates will be compared between the two treatment groups.
|
Through study completion, average 1 year
|
1-year mortality rates
Time Frame: Through study completion, average 1 year
|
These will be compared between the two groups.
|
Through study completion, average 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert Storey, Sheffield Teaching Hospitals NHS FT
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH19902
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
Clinical Trials on Enoxaparin
-
Indonesia UniversityPT Metiska FarmaCompleted
-
Oregon Health and Science UniversityNational Trauma Research Institute; Medical Research Foundation, OregonCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
University of OuluUniversity of HelsinkiUnknownIntracerebral HemorrhageFinland
-
Peking Union Medical College HospitalCompletedCoronary Artery Disease | Percutaneous Coronary InterventionChina
-
Portola PharmaceuticalsCompleted
-
University of UtahUniversity of MichiganCompletedSurgery | Venous Thromboembolism | Deep Venous ThrombosisUnited States
-
Lebanese American UniversityCompletedRenal Impairment | Venous ThromboembolismLebanon
-
PT Bio FarmaRecruiting
-
Wake Forest University Health SciencesTerminated